What is Hesperos?
Hesperos, Inc. stands as a pioneer in the development of Human-on-a-Chip microfluidic systems, a transformative technology designed to characterize individual biology with unprecedented precision. Founded by industry luminaries Michael L. Shuler and James J. Hickman, the firm has established itself as a leader in creating interconnected multi-organ systems. These pumpless platforms utilize serum-free cellular mediums to facilitate authentic multi-organ communication, enabling integrated computational PKPD modeling. By providing functional readouts from diverse tissues—including neurons, cardiac, muscle, and barrier tissues—Hesperos is effectively revolutionizing the standards for toxicology testing and drug efficacy evaluation. The company's ability to simulate live physiological responses provides a critical bridge between preclinical research and clinical outcomes, positioning it as an essential partner for global drug discovery initiatives.
How much funding has Hesperos raised?
Hesperos has raised a total of $235K across 2 funding rounds:
Debt
$150K
Debt
$85K
Debt (2020): $150K with participation from PPP
Debt (2021): $85K led by PPP
Key Investors in Hesperos
PPP
Public-Private Partnership
What's next for Hesperos?
With this late-stage financing, Hesperos is poised to scale its operational capacity and broaden the application of its multi-organ systems. The strategic deployment of this capital will likely focus on enhancing the throughput of its toxicology testing platforms and expanding its footprint in the drug discovery market. As the industry shifts toward more predictive, non-animal testing models, Hesperos is well-positioned to capitalize on the growing demand for high-fidelity physiological data. Future growth will likely involve deepening partnerships with major pharmaceutical entities and refining its computational modeling capabilities to further reduce the time and cost associated with bringing new therapeutics to market.
See full Hesperos company page
